Kioxia Targets U.S. Listing as AI Chip Boom Accelerates 
Nike CFO Shake-Up Fuels Concerns Over Turnaround Strategy 
Tesla and NatPower Partner on $5 Billion Battery Storage Expansion in Europe 
Baseten Secures $1.5 Billion Funding at $13 Billion Valuation Amid AI Infrastructure Boom 
Nissan Halts Electric Qashqai Development Amid EV Market Challenges 
Micron Stock Surges on Strong AI Demand, Record Revenue, and Bullish Q4 Forecast 
SK Hynix Targets $29.4 Billion Nasdaq Listing to Expand AI Chip Business 
Meta Reportedly Developing ‘Arena’ Prediction Market App to Rival Polymarket and Kalshi 
Cerebras Revenue Forecast Tops Expectations, but Margin Concerns Weigh on Stock 
SK Hynix Moves Closer to New York ADR Listing Amid AI Chip Boom 
SpaceX Stock Rebounds After Sharp Selloff, But Valuation Concerns Persist 
Doncasters Raises $919 Million in NYSE IPO as Aerospace Growth Accelerates 
Ryan Cohen Rejects GameStop Pay Package, Prepares New eBay Acquisition Plan 
Bain Capital Nears Deal for Majority Stake in Volkswagen Marine Engine Unit Everllence 
Trump Orders DOJ Investigation Into Exxon, Chevron Over High Gas Prices 
DOJ Opens Investigation Into NYC Coffee Shop Over Anti-Goldman Social Media Post 
KPMG Australia Chairman and Senior Partners Exit Amid Escalating Whistleblower Scandal 
HEIDELBERG, Germany, Feb. 29, 2016 -- Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, announced today that Dr. Florian Fischer, CFO, will present at the Cowen and Company 36th Annual Health Care Conference on Monday, March 7, 2016 at 3:20 p.m. (ET) in Boston.
To access a simultaneous webcast of Dr. Fischers' presentation at the Conference online, log on to http://wsw.com/webcast/cowen30/afmd or go to the "Events" section on the "Media" page of the Affimed website at http://www.affimed.com/events.php. A replay of the webcast will be available from Affimed's website for 30 days following the conference. Dr. Fischers' presentation will be available for download in PDF format immediately following the conference presentation in the "Events" section of the Media page of Affimed's website at http://www.affimed.com/events.php.
About Affimed N.V.
Affimed (Nasdaq: AFMD) is a clinical-stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies. Affimed's product candidates are being developed in the field of immuno-oncology, which represents an innovative approach to cancer treatment that seeks to harness the body's own immune defenses to fight tumor cells. The most potent cells of the human defense arsenal are types of white blood cells called natural killer cells, or NK-cells, and T-cells. Affimed's proprietary, next-generation bispecific antibodies, called TandAbs for their tandem antibody structure, are designed to direct and establish a bridge between either NK-cells or T-cells and cancer cells, triggering a signal cascade that leads to the destruction of cancer cells. Affimed has focused its research and development efforts on three proprietary TandAb programs for which it retains global commercial rights. For more information, please visit www.affimed.com.
IR Contact:
Caroline Stewart, Head IR
Phone: +1 347394 6793
E-Mail: [email protected] or [email protected]
Media Contact:
Anca Alexandru, Head of Communications
Phone: +49 6221 64793341
E-Mail: [email protected]
HUG#1989860
